Key Takeaways RMD's Q4 adjusted EPS rose 22.6% to $2.55, beating estimates and driven by strong global performance.RMD's revenues grew 10.2% to $1.35B, fueled by solid gains in devices, masks and Residential Care Software.RMD's adjusted gross margin rose 227 bps to 61.4%, supported by cost efficiencies and currency tailwinds.Resmed Inc.’s (RMD) adjusted earnings per share (EPS) in the fourth quarter of fiscal 2025 were $2.55, up 22.6% year over year. The metric beat the Zacks Consensus Estimate by 3.66%.The ...